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The purpose of this teaching lecture is to examine typical approaches 
for representation of patient anatomical data in treatment planning 
systems and the impact of that representation on the accuracy of dose 
calculation. 
Dose calculation in modern treatment planning systems, which can 
often report dose to water or dose to medium, require mass density 
and tissue composition information for accurate kernel scaling and 
radiation transport. The planning systems use patient specific anatom-
ic information in the form of high-resolution CT images for volume 
definition and dose calculation.  CT information is obtained at kV 
energies so in order to obtain the relevant properties required for use 
in high energy photon or proton beams, the CT numbers are converted 
to electron density or proton stopping powers using calibration curves 
obtained using phantoms with known properties.  Following this, the 
patient data is resampled into a more coarse matrix and then seg-
mented into a limited number of tissue types based on, for example, 
data from ICRU44 or ICRP23, which are themselves obtained from 
population based data sets. Dose calculations are performed on these 
converted, re-sampled data sets and output as distributions on the 
original high resolution CT image set. Errors at the conversion stage 
can propagate through to dose calculation and the number of tissue 
sets used in the conversion process has been shown to have an effect 
on the dose calculation. In particular, for low energy ranges including 
brachytherapy energies, it has been shown the assignment of tissue 
properties can significantly affect dose calculation accuracy. Typical 
processes, including stoichiometric approaches, for converting CT 
data to tissue types will be described and recent data from a number 
of researchers showing the influence of the choice of conversion on 
dose calculation accuracy will be presented.   
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In-room patient imaging started in the 1950s. Different initiatives 
were taken to monitor and improve patient’s treatment positioning. 
Not earlier then the 1990s Electronic Portal Imaging (EPI) was devel-
oped and became commercially available. The development of EPI 
much improved both the process and the quality of the verification of 
the treatment position. The role of EPI grew and became an important 
part in the quality assurance (QA) chain of radiotherapy.  
In the last decade, 3D volumetric imaging was introduced. Nowadays 
most vendors have some kind of 3D imaging device commercially 
available. One advantage of 3D imaging is the improved quality of 
patient registration. Different studies showed improved registration 
accuracy as compared to 2D EPI. Another advantage is the ability to 
register patients directly to the tumour, e.g. in case oflung cancer. 
This not only contributed to the widespread application of Stereotac-
tic Body RadioTherapy (SBRT), but it also resulted in more insight in 
fundamental processes like the baseline shift of lung tumours. Know-
ledge about these processes further underlined the importance of 3D 
image guidance. 
More recent, the application of Adaptive Radiotherapy (ART) has 
increased and in-room volumetric imaging is a basic requirement for 
many types of the sophisticated treatment. For instance, in the Plan-
of-the-day concept a treatment plan is selected daily from a library of 
plans based on the actual size/shape of the tumour as visualised with 
Conebeam-CT (CBCT) images. This type of treatment has been intro-
duced for treatment sites like cervix and bladder cancer. Develop-
ments like ART force us to look at the changing physiology and pathol-
ogy of patients. There is a growing evidence, however, for monitoring 
anatomical changes over the course of radiotherapy in general. 
Changes in body contour for instance can be assessed easily with 3D 
imaging. A retrospective analysis of Conebeam-CT (CBCT) images from 
the NKI showed the need of replanning at some point in the treatment 
course in 15% patients treated for lung cancer. 
Besides monitoring patient position and anatomical changes, 3D 
imaging can also be used for QA goals. Questions regarding the posi-
tion of the patient relative to their immobilisation devices can be 
investigated using 3D images: e.g. is the right knee-support used, or is 
the patient well positioned on the used belly board device? In some 
cases this might give us an explanation for unstable or incorrect 
patient positioning. Also, the quality of (individual) built-up materials 
and their application can be monitored. 
With all these new possibilities the need for a systematic analysis of 
3D images is born. We no longer can perform image registration in 
terms of translation and rotations only. Ideally, the acquired images 
should be analysed on chancing anatomy and immobilization quality 
systematically, or at least at different moments during the treatment 
of the patient. Furthermore, we need to have a strategy on how to 
act when the anatomy no longer resembles the situation on the inia-
tial reference CT-scan. A protocolised method for evaluating the 
effects of anatomical changes, e.g. by recalculating the actually given 
dose using the CBCT image, would be a necessity. But maybe the most 
challenging part is finding the time and resources to be able to truly 
utilize all benefits that volumetric imaging is offering us. 
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Patient reported outcomes (PRO) are of increasing interest as meas-
ures of disease- and treatment-related outcomes after radiotherapy. 
They have long been accepted in the palliative setting, but it is only 
recently that a primary role in the curative setting has been investi-
gated. This interest is stimulated, not only by the validity and reliabil-
ity of PRO, but also by their relative ease of administration and 
collection.  
PRO can be restricted to recording specific disease- and treatment-
related symptoms or extended to include broader qualities such as 
emotional well-being, social and sexual functioning and overall satis-
faction with life. Fully-validated multi-item questionnaires are availa-
ble, including some that are not cancer specific (MOS SF36, EQ5D) and 
others that are cancer non-site specific (EORTC QLQ-C30), cancer site 
specific (EORTC QLQ-BR23) and treatment specific (FACT N, for 
neutropenic sepsis). The identification of questionnaire(s) appropriate 
for a specific clinical context is extremely important, and requires 
expert guidance. Assuming research questions are precisely defined 
and the appropriate PRO measures are fully incorporated in the 
analysis plan, questionnaires need to be administered to patients by 
trained staff with the time to explain how to respond to the ques-
tions. As with clinician assessments, >10% missing data present serious 
problems to analysis and interpretation, since reasons for missing data 
may be linked to the outcomes under study. 
UK breast hypofractionated radiotherapy trials are among several 
studies that illustrate the potential power of PRO in research. PRO of 
breast shrinkage and hardness perform as well as change in photo-
graphic breast appearance scored by independent observers in discri-
minating small differences in randomised dose, and generate compa-
rable estimates of α/β for endpoints such as change in breast size and 
hardness. This is despite limited concordance between clinician and 
self-assessments at the level of individual patients. Although no trial 
testing curative radiotherapy has yet abandoned clinical assessments 
of treatment outcome, this may be only a matter of time. Finally, 
although PRO and standard external assessments can function well as 
therapeutic endpoints, they do not necessarily distinguish between 
the relevant pathological processes (atrophy, fibrosis, telangiectasia 
etc), a requirement that may prove essential in correlative research 
into genetic susceptibilities. 
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Traditionally, treatment planning in brachytherapy has been based 
upon 2D imaging and specific points have been used for prescription 
and reporting. With the introduction of image guided brachytherapy 
(IGBT) it has been possible to move from point prescription to pre-
scription of dose to 3D target volume in terms of dose volume histo-
gram parameters.  
In radiotherapy in general, it is essential to use a common language in 
order to compare clinical results from different centres worldwide. 
Applying IGBT it is important to use a terminology adjusted to the 
complex nature of such treatment technique. Preferably the same 
terminology should be used for different brachytherapy sites. It should 
also be harmonized, as far aspossible, to the terminology used in 
external beam radiotherapy (EBRT), e.g. ICRU83. 
Several recommendations on 3D image based treatment planning have 
been published for various brachytherapy sites the last ten years. In 
an upcoming ICRU/GEC ESTRO recommendation for cervical cancer 
brachytherapy, concepts and terms for target and OAR definitions, 
biological dose modelling and DVH parameters are described for IGBT. 
